Report – Expert Analysis: 22 years of FDA Drug GMP 483s

Webinar – Insights from Mapping API Inspection Deficiencies to the Quality Systems

Webinar – Legal Considerations | Interacting with the FDA Before, During, and After Inspections

Webinar – Quality Intelligence: from Information to Knowledge

Report – Analysis of FDA 483s Issued to Excipient Manufacturers Since 2000

Webinar – Comparing Inspection Observations between FDA and Health Canada

Report – Analysis of FDA Drug GMP Warning Letters for FY2022

Report – Breaking News: The First FDA Warning Letter to an Excipient Manufacturer

Report – Insights on Quality from FDA Leaders

Webinar – Data Integrity and Quality Culture – Enabling far more than “just” compliance
« Older Entries
Newer Entries »